HIGHLIGHTS
- who: Frederik O. Meeuwes from the Department of Hematology, Treant Hospital, Emmen, the Department of Hematology, University Medical Center Groningen, Groningen, the have published the research: Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis, in the Journal: (JOURNAL)
- what: This study reports the largest nationwide and population-based cohort published on this subject thus far.
SUMMARY
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive, mature T-cell lymphoproliferative neoplasm that is classified as one of the peripheral T-cell lymphomas (PTCL). In . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.